PNC Financial Services Group Inc. Sells 1,154 Shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

PNC Financial Services Group Inc. decreased its holdings in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) by 4.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 23,903 shares of the company’s stock after selling 1,154 shares during the quarter. PNC Financial Services Group Inc.’s holdings in SPDR S&P Pharmaceuticals ETF were worth $1,060,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in XPH. Angeles Wealth Management LLC acquired a new position in shares of SPDR S&P Pharmaceuticals ETF during the second quarter worth approximately $40,000. AlphaMark Advisors LLC acquired a new position in SPDR S&P Pharmaceuticals ETF during the 2nd quarter valued at $234,000. Commonwealth Equity Services LLC raised its stake in SPDR S&P Pharmaceuticals ETF by 8.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 7,364 shares of the company’s stock valued at $293,000 after purchasing an additional 602 shares during the last quarter. CX Institutional boosted its holdings in SPDR S&P Pharmaceuticals ETF by 117.2% in the 2nd quarter. CX Institutional now owns 9,711 shares of the company’s stock valued at $386,000 after purchasing an additional 5,240 shares during the period. Finally, U.S. Capital Wealth Advisors LLC grew its position in SPDR S&P Pharmaceuticals ETF by 44.1% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 18,066 shares of the company’s stock worth $719,000 after purchasing an additional 5,531 shares during the last quarter.

SPDR S&P Pharmaceuticals ETF Stock Performance

Shares of XPH opened at $46.28 on Thursday. The company has a 50-day simple moving average of $45.67 and a 200-day simple moving average of $43.15. SPDR S&P Pharmaceuticals ETF has a 52 week low of $36.49 and a 52 week high of $48.76. The firm has a market capitalization of $224.46 million, a P/E ratio of 14.39 and a beta of 0.87.

SPDR S&P Pharmaceuticals ETF Profile

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.